Tag: FTC decision on Novo Holdings and Catalent deal
Novo Holdings to Finalize $16.5B Acquisition of Catalent as FTC Approves Deal
Novo Holdings, the parent company of Novo Nordisk, is set to finalize its $16.5 billion acquisition of Catalent, a prominent contract drug manufacturer, as the U.S. Federal Trade Commission (FTC) greenlights the deal, signaling...